Amgen's ROE % for the quarter that ended in Jun. 2023 was 90.96%. Amgen's PB Ratio for the quarter that ended in Jun. 2023 was 17.51.
Amgen's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2023 was 5.19%.
Amgen ROE % Adjusted to Book Value Historical Data
The historical data trend for Amgen's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Amgen Annual Data
Trend
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
ROE % Adjusted to Book Value
4.53
4.80
5.39
3.90
3.30
Amgen Quarterly Data
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
ROE % Adjusted to Book Value
5.87
8.58
4.61
10.45
5.19
Competitive Comparison
For the Drug Manufacturers - General subindustry, Amgen's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amgen ROE % Adjusted to Book Value Distribution
For the Drug Manufacturers industry and Healthcare sector, Amgen's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Amgen's ROE % Adjusted to Book Value falls into.
Amgen ROE % Adjusted to Book Value Calculation
Amgen's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amgen ROE % Adjusted to Book Value Related Terms
Thank you for viewing the detailed overview of Amgen's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amjevita (biosimilar Humira).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
5.3(1.99%) Volume: 2,315,969 11:08PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
AMGN has been successfully added to your 
